Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study evaluates prognostic value of molecule CD44v6 in women with brest cancer
August 18th, 2005
Study evaluates the prognostic value of adhesion molecule CD44v6 in women with breast cancer. According to a study from the United States, "CD44 functions as an adhesion molecule. Within the family of CD44 isoforms, the spliced variant 6 has been causally associated with the development of metastases and poor prognosis in animal models and several human cancers." "The aim of this study was to investigate the prognostic value of CD44v6 in women with primary breast carcinoma. Women with primary breast carcinoma in this study were followed up clinically for a period of 5 years. Clinicopathologic features, including turnout size, axillary nodal status,...
Source: Women's Health Weekly (2005-08-18)
|
